Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham heart study)

被引:67
作者
Sam, C
Massaro, JM
D'Agostino, RB
Levy, D
Lambert, JW
Wolf, PA
Benjamin, EJ
机构
[1] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA
[2] Emory Univ, Sch Med, Div Gen Med, Atlanta, GA USA
[3] Boston Univ, Sch Med, Dept Cardiol Prevent Med & Neurol, Boston, MA 02118 USA
[4] Boston Univ, Dept Math, Boston, MA 02215 USA
[5] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
[6] Beth Israel Deaconess Med Ctr, Div Cardiol & Clin Epidemiol, Boston, MA 02215 USA
[7] Natl Heart Lung & Blood Inst, Bethesda, MD USA
关键词
D O I
10.1016/j.amjcard.2004.06.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Framingham Heart Study records of participants with atrial fibrillation (AF) during 1980 and 1994 were retrospectively reviewed to determine the prevalence of warfarin and aspirin use in AF. Anticoagulant use increased significantly in the 393 men and women (mean ages 72.5 and 79.0 years, respectively) who developed AF over the observation period: aspirin use increased from 14% to 39% in men and from 19% to 33% in women, and warfarin use increased from 10% to 39% in men and from 17% to 38% in women. There were no significant gender differences in anticoagulant use (p = 0.61), but participants using warfarin were younger. A total of 65 participants (17%) had major bleeding complications less than or equal to5 years after initial AF. Age was not a significant predictor of bleeding. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:947 / +
页数:6
相关论文
共 20 条
  • [1] Abbott R.D., 1987, The Framingham Study: an epidemiological investigation of cardiovascular disease
  • [2] Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a veterans affairs medical center
    Bradley, BC
    Perdue, KS
    Tisdel, KA
    Gilligan, DM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (05) : 568 - 572
  • [3] CHOBANIAN AV, 2003, JAMA-J AM MED ASSOC, V289, P2650
  • [4] CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY
    CONNOLLY, SJ
    LAUPACIS, A
    GENT, M
    ROBERTS, RS
    CAIRNS, JA
    JOYNER, C
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) : 349 - 355
  • [5] AN APPROACH TO LONGITUDINAL STUDIES IN A COMMUNITY - FRAMINGHAM STUDY
    DAWBER, TR
    KANNEL, WB
    LYELL, LP
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1963, 107 (02) : 539 - &
  • [6] Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?
    Evans, A
    Kalra, L
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (11) : 1443 - 1447
  • [7] WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION
    EZEKOWITZ, MD
    BRIDGERS, SL
    JAMES, KE
    CARLINER, NH
    COLLING, CL
    GORNICK, CC
    KRAUSESTEINRAUF, H
    KURTZKE, JF
    NAZARIAN, SM
    RADFORD, MJ
    RICKLES, FR
    SHABETAI, R
    DEYKIN, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) : 1406 - 1412
  • [8] RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY
    FIHN, SD
    MCDONELL, M
    MARTIN, D
    HENIKOFF, J
    VERMES, D
    KENT, D
    WHITE, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) : 511 - 520
  • [9] Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Borowsky, LH
    Phillips, KA
    Selby, JV
    Singer, DE
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (12) : 927 - +
  • [10] RISK-FACTORS FAR INTRACRANIAL HEMORRHAGE IN OUTPATIENTS TAKING WARFARIN
    HYLEK, EM
    SINGER, DE
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 120 (11) : 897 - 902